Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review Ulrik CSInt J Chron Obstruct Pulmon Dis 2014[]; 9 (ä): 331-8BACKGROUND AND AIM: Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the clinical efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium bromide in patients suffering from COPD. METHODS: This study comprised a systematic review of randomized controlled trials identified through systematic searches of different databases of published trials. RESULTS: Nine trials (6,166 participants) were included. Fixed-dose once-daily indacaterol/glycopyrronium seems to be safe and well tolerated in patients with COPD. Compared with single therapy with other long-acting bronchodilators (indacaterol, glycopyrronium, and tiotropium) and fixed-combination long-acting beta2-agonist/inhaled corticosteroid (salmeterol/fluticasone twice daily), once-daily fixed-dose indacaterol/glycopyrronium has clinically important effects on symptoms, including dyspnea score, health status, level of lung function, and rate of moderate or severe exacerbations in patients with moderate-to-very severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] spirometric criteria). Furthermore, a very recent study has shown that fixed-dose indacaterol/glycopyrronium improves exercise endurance time compared with placebo, although no significant difference was observed between fixed-dose indacaterol/glycopyrronium and tiotropium. CONCLUSION: Fixed-dose indacaterol/glycopyrronium has clinically relevant effects on important COPD outcome measures and is, in general, superior to therapy with a single long-acting bronchodilator (with or without inhaled corticosteroid) indicating long-acting dual bronchodilation as a potential important maintenance therapeutic option for patients with symptomatic COPD, possibly also for the treatment of naive patients.|Administration, Inhalation[MESH]|Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects[MESH]|Bronchodilator Agents/*administration & dosage/adverse effects[MESH]|Drug Administration Schedule[MESH]|Drug Combinations[MESH]|Glycopyrrolate/*administration & dosage/adverse effects[MESH]|Humans[MESH]|Indans/*administration & dosage/adverse effects[MESH]|Lung/*drug effects/physiopathology[MESH]|Muscarinic Antagonists/*administration & dosage/adverse effects[MESH]|Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology[MESH]|Quinolones/*administration & dosage/adverse effects[MESH]|Randomized Controlled Trials as Topic[MESH]|Recovery of Function[MESH]|Time Factors[MESH]|Treatment Outcome[MESH] |